Evidence map›Paper›PMID 33433659›Full record

ArticleJournal of cancer research and clinical oncology2021

Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).

Tanja Holzhey, Wolfram Pönisch, Song-Yau Wang, Madlen Holzvogt, Bruno Holzvogt, Marc Andrea, Thomas Zehrfeld, Doreen Hammerschmidt, Franz Albert Hoffmann, Cornelia Becker and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Tanja HolzheyHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Wolfram PönischHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, Liebigstraße 22, 04103, Leipzig, Germany. Wolfram.Poenisch@medizin.uni-leipzig.de.ORCID http://orcid.org/0000-0002-9666-6274
Song-Yau WangHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Madlen HolzvogtHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Bruno HolzvogtHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Marc AndreaHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Thomas ZehrfeldHospital Torgau, Christianistraße 1, 04860, Torgau, Germany.
Doreen HammerschmidtHELIOS Vogtland - Klinikum Plauen, Röntgenstraße 2, 08529, Plauen, Germany.
Franz Albert HoffmannHematology Practice, Biedermannstraße 84, 04277, Leipzig, Germany.
Cornelia BeckerHematology Practice, Biedermannstraße 84, 04277, Leipzig, Germany.
Andreas SchwarzerHematology Practice, Strümpellstraße 42, 04289, Leipzig, Germany.
Maik SchwarzMedical Care Center Schöneck, Albertplatz 1, 08261, Schöneck, Germany.
Uta Schönfelder-FrickeHematology Practice, Lütznerstraße 162, 04179, Leipzig, Germany.
Thomas EdelmannHematology Practice, Theodor - Heuss-Str. 2, 04435, Schkeuditz, Germany.
Leanthe BraunertHematology Practice, Theodor - Heuss-Str. 2, 04435, Schkeuditz, Germany.
Georg-Nikolaus FrankeHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Madlen JentzschHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Sebastian SchwindHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Markus BillHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Juliane GrimmHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Yvonne RemaneClinic Pharmacy, University of Leipzig, Liebigstraße 20, 04103, Leipzig, Germany.
Uwe PlatzbeckerHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Markus ScholzInstitute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Härtelstraße 16-18, 04107, Leipzig, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLight chain involvement is observed in almost every patient (pt) with newly diagnosed multiple myeloma (MM). Owing to a relatively short half-life, rapid reduction in the involved free light chain (iFLC) is of potential prognostic value.

methodsThis retrospective analysis included 92 pts with newly diagnosed MM treated with bendamustine, prednisone, and bortezomib (BPV).

resultsAfter a median number of two (range 1-5) BPV cycles, the majority of pts (n = 86; 93%) responded with either sCR (n = 21), CR (n = 1), nCR (n = 25), VGPR (n = 20), or PR (n = 19). PFS and OS at 48 months were 39% and 67%, respectively. At baseline, 79 out of 92 pts (86%) had iFLC levels above the upper standard level and an abnormal ratio of involved to uninvolved free light chain ≥ 8. In a subgroup analysis of these pts, we evaluated the prognostic importance of an early reduction of the iFLC during the first two BPV cycles. A reduction ≥ 50% of the iFLC on day 8 of the first cycle was observed in 31 of 69 pts. These pts had a significantly better median PFS of 49 months as compared to 20 months in 38 pts with a lower iFLC reduction (p = 0.002). In contrast, OS did not differ significantly with a 48 months survival of 77% vs 69% (p > 0.05).

conclusionThese results indicate that a rapid decrease in the iFLC on day 8 is an early prognostic marker for newly diagnosed MM pts undergoing BPV treatment.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBiomarkers, TumorBortezomibFemaleHumansImmunoglobulin Light ChainsMaleMiddle AgedMultiple MyelomaNeoadjuvant TherapyPredictive Value of TestsPrednisoneBendamustine HydrochlorideBiomarkers, TumorBortezomibImmunoglobulin Light ChainsPrednisoneBendamustineBortezomibFirst-line treatmentInvolved free light chainMultiple myeloma

Identifiers

PMID33433659
PMCPMC8236483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.